Clarity Pharmaceuticals Ltd. · ASX:CU6
Clarity Pharmaceuticals — Wilson's Drug and Device Conference (October 2023)
13 slides from Clarity Pharmaceuticals's conference presentation, Oct 27, 2023
Slide 1: Wilson's Drug and Device Conference
Wilson’s Drug and Device Conference Developing the next-generation of radiopharmaceuticals to improve treatment outcomes for children and adults with cancer 27 October 2023 Dr Alan Taylor Dr Colin Biggin Executive Chairperson Managing Director E: alan.taylor@claritypharm.com E: colin.biggin@clarityp
Slide 2: Disclaimer
Disclaimer Introduction This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (Clarity or the Company) No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking and contains summary information about Clarity and t
Slide 3: Clarity in a nutshell (ASX:CU6)
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical Clarity in a nutshell (ASX:CU6) company developing next-generation products to address the growing need for better diagnostics and treatments in oncology SAR Technology Platform Proprietary Global leader in Significant supply, A proprie
Slide 4: Current industry challenges with 68Ga & 177Lu vs Clarity's TCT Solution with 64Cu & 67Cu
Current industry challenges with 68Ga & 177Lu Clarity’s TCT Solution with 64Cu & 67Cu Additional demands on existing supply as industry grows Global scale commercial Time sensitive capacity for diagnostics Inability to control products with and therapeutics short shelf-lives the entire supply chain
Slide 5: Next-generation theranostics provide solutions to the challenges with current-generation radiopharmaceuticals
Next-generation theranostics provide solutions to the challenges with current-generation radiopharmaceuticals Opportunities with 64Cu (half-life = 12.7h) Opportunities with Rhodotron produced 67Cu • Can be mass produced on cyclotrons with solid targetry • Commercially available • Every US zip code c
Slide 6: Three core product areas in US clinical trials
Three core product areas in US clinical trials Clarity has potential to address multiple oncology indications with unmet needs through a range of products and their applications. These include large indications, such as prostate and breast cancers, as well as small and orphan indications, such as ne
Slide 7: SAR-bisPSMA market opportunity
SAR-bisPSMA market opportunity SAR-bisPSMA aims to disrupt current diagnostic and therapeutic utilisation with a best-in-class agent for imaging and treating prostate cancer PSMA based diagnostics PSMA based therapy (mCRPC) • Current US patient pool for PSMA-PET imaging is • Current US patient pool
Slide 8: Not all PSMA targeting agents are created equal
Not all PSMA targeting agents are created equal 64Cu/67Cu Superior performance of SAR-bisPSMA compared to monomer SAR-PSMA Radioisotope Cage SAR “chelator” securely SAR-bisPSMA has higher holding the radioisotope Targeting uptake in tumours and strong Molecules retention compared to PSMA Two PSMA mo
Slide 9: Diagnostic program with 64Cu SAR-bisPSMA
Diagnostic program with Initial staging– Clarity’s PROPELLER study 64Cu SAR-bisPSMA Comparison of 68Ga PSMA-11 (image left) to Clarity’s 64Cu SAR-bisPSMA (image right) in the same patient Improved uptake of SAR-bisPSMA may support better diagnosis compared to first-generation PSMA PET agents. 68Ga P
Slide 10: Therapy program with 67Cu SAR-bisPSMA
Therapy program with 67Cu SAR-bisPSMA Currently recruiting into cohort 3 in the US-based study Trial highlights to date Trial overview • Now recruiting in cohort 3 at 12GBq dosing (Pluvicto dose capped at 7.4GBq) • Phase I/II study in mCRPC • 100% of patients in cohort 2 had a PSA decline • Particip
Slide 11: 67Cu SAR-bisPSMA therapy Phase I/II SECURE trial in mCRPC
67Cu SAR-bisPSMA therapy Phase I/II SECURE trial in mCRPC : 64Cu SAR-bisPSMA PET/CT imaging before and after a single cycle of 8GBq 67Cu SAR-bisPSMA Cohort 2 PSA decrease following (n=3) single therapy cycle 1 >95% PSA 47.2 May 23 2 >99% 3 >80% Considerable reduction in uptake of 64Cu SAR-bisPSMA on
Slide 12: Summary
Summary Global leader in Targeted Copper Theranostics (TCTs) • Extensive pipeline of TCTs based on 64Cu for diagnosis and 67Cu for therapy • Multiple therapeutic and diagnostic trials in progress with Phase III clinical trials commencing from 2023 • TCTs address the current manufacturing and logisti
Slide 13: Thank you
Thank you Contact details Dr Colin Biggin Dr Alan Taylor Managing Director and CEO Executive Chairperson E: colin.biggin@claritypharm.com E: alan.taylor@claritypharm.com
Clarity Pharmaceuticals — Wilson's Drug and Device Conference (October 2023) on 6ix